Kuros Aktie
| 20,65CHF | -0,95CHF | -4,40% |
WKN DE: A2ALS5 / ISIN: CH0325814116
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 66,31 |
| C A C M Oomen | 24,86 |
| Pegasus Global Opportunity Fund Ltd. | 5,75 |
| CS Fund 3 - Small Cap Switzerland Equity Fund | 4,41 |
| Joost D. de Bruijn, PhD | 3,89 |
| Kuros Biosciences Ltd. | 3,09 |
| Banque Pictet & Cie SA | 2,92 |
| Credit Suisse Asset Management (Schweiz) AG | 2,91 |
| APO Medical Opportunities | 2,81 |
| APO VV Premium Privat | 2,81 |
| BlackRock Global Funds - Swiss Small & Mid Cap Opp. Fd. | 1,55 |
| Swisscanto (CH) Index Fund V - Equity Fd. Switzerland To. Res. | 0,89 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 6 | 5 | 6 | 6 | 5 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,43 | 0,81 | 2,30 | 3,00 | 6,71 |
Bilanz (in Mio. CHF) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 23 | 34 | 33 | 31 | 27 |
| Summe Anlagevermögen | 67 | 64 | 63 | 57 | 49 |
| Summe Aktiva | 90 | 98 | 96 | 88 | 76 |
Bilanz (in Mio. CHF) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 12 | 13 | 19 | 19 | 19 |
| Summe Eigenkapital | 78 | 85 | 77 | 69 | 57 |
| Summe Passiva | 90 | 98 | 96 | 88 | 76 |
Adresse
| Wagistrasse 25, 8952 Schlieren | |
| Telefon | +41 (44) 733-47-47 |
| Fax | +41 (44) 733-47-40 |
| Internet | http://kurosbio.com |
Management
|
Albert Arp
Non-Executive Director |
|
Christopher T. Fair
Chief Executive Officer |
|
Clemens A. van Blitterswijk
Chairman |
|
Daniel Geiger
Chief Financial Officer |
|
Florence Barrère de Groot
Vice President-Research & Development |
|
Joe Ross
Senior VP-Marketing & Business Development |
|
John Griffin
Chief Commercial Officer |
|
Joost D. de Bruijn
Executive Director & President-Innovation |
|
Katherine Sage
Senior Vice President-Medical & Clinical Affairs |
|
Luuk van Dijk
Manager-Medical & Scientific Affairs |
|
Marcel Borger
Head-Quality & Regulatory Affairs |
|
Nikki Coleman
Vice President-Global Human Resources |
|
Oliver Walker
Independent Non-Executive Director |
|
Philippe Saudan
Chief Development Officer |
|
Sjoerd Musters
Chief Operating Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
